These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36307004)

  • 1. Withdrawal of Denosumab in Patients With Primary Hyperparathyroidism: A Follow-up Report of the DENOCINA Study.
    Leere JS; Majgaard J; Leere MZP; Overby AC; Vestergaard P
    Endocr Pract; 2022 Dec; 28(12):1226-1231. PubMed ID: 36307004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Leere JS; Karmisholt J; Robaczyk M; Lykkeboe S; Handberg A; Steinkohl E; Brøndum Frøkjær J; Vestergaard P
    Lancet Diabetes Endocrinol; 2020 May; 8(5):407-417. PubMed ID: 32333877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism.
    Eller-Vainicher C; Palmieri S; Cairoli E; Goggi G; Scillitani A; Arosio M; Falchetti A; Chiodini I
    J Am Geriatr Soc; 2018 Mar; 66(3):518-524. PubMed ID: 29364518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients.
    McKee H; Ioannidis G; Lau A; Treleaven D; Gangji A; Ribic C; Wong-Pack M; Papaioannou A; Adachi JD
    Osteoporos Int; 2020 May; 31(5):973-980. PubMed ID: 31900542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
    Shimizu T; Arita K; Murota E; Hiratsuka S; Fujita R; Ishizu H; Asano T; Takahashi D; Takahata M; Iwasaki N
    J Bone Miner Metab; 2021 Sep; 39(5):868-875. PubMed ID: 33847831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
    Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment.
    Hirooka Y; Nozaki Y; Inoue A; Li J; Shiga T; Kishimoto K; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Bone Rep; 2020 Dec; 13():100293. PubMed ID: 32676524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism.
    Miyaoka D; Imanishi Y; Kato E; Toi N; Nagata Y; Kurajoh M; Yamada S; Inaba M; Emoto M
    Endocrine; 2020 Sep; 69(3):642-649. PubMed ID: 32621048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman F; Crittenden DB; Ferrari S; Khan A; Lane NE; Lippuner K; Matsumoto T; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2018 Jul; 33(7):1219-1226. PubMed ID: 29573473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial.
    Cosman F; McMahon D; Dempster D; Nieves JW
    J Bone Miner Res; 2020 Feb; 35(2):219-225. PubMed ID: 31419313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.
    Kobel C; Frey D; Graf N; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2019; 44(5):1285-1293. PubMed ID: 31614356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.
    Doria C; Leali PT; Solla F; Maestretti G; Balsano M; Scarpa RM
    Clin Cases Miner Bone Metab; 2016; 13(3):195-199. PubMed ID: 28228781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
    Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.